作者对 “食品和药品管理局不良事件报告系统中与胰高血糖素样肽 1 受体激动剂相关的甲状腺增生和肿瘤不良事件 : 回顾性分析 ” 的同行评论的回应。
关键词: FDA Food and Drug Administration GLP adverse cancer cancers drug drugs glucagon-like peptide-1 medication medications monotherapy neoplasm neoplasms oncology pharmaceutic pharmaceutical pharmaceuticals pharmaceutics pharmacies pharmacology pharmacotherapy pharmacy reporting thyroid
来 源: DOI:10.2196/58273 PDF(Pubmed)